Stereotactic body radiotherapy (SBRT) has become a new therapeutic option for primary renal cell carcinoma. However, treatment doses lack consistency in the literature. The primary objective of this study was to determine the maximum tolerated dose for renal cancer SBRT.
This phase I multicentric dose-escalation study assessed four dose levels: 8 Gy x 4, 8 Gy x 5, 10 Gy x 4 and 12 Gy x 4. The primary objective of this study was to determine the Maximal Tolerated Dose, defined by the occurrence of Dose Limiting Toxicity (DLT). DLT was defined as any CTCAE v4.0 grade ≥ 4 acute side effect.
From October 2010 to September 2017, 13 patients were enrolled. Median follow-up was 23 months. There were no DLT in our study and the highest dose was reached successfully. No acute or late toxicity above grade 2 was seen. There was no significant alteration of renal function after treatment. At 24 months, 2 patients had partial response and the others had stable disease.
After 24 months of follow-up, no dose-limiting toxicity was seen at any of the prescribed dose-level in our study. As such, our last dose level of 48 Gy in four 12 Gy fractions can be considered safe and can be used in further studies.
Practical radiation oncology. 2022 Jul 13 [Epub ahead of print]
Ariane Lapierre, Lionel Badet, Olivier Rouviere, Gilles Crehange, Julien Berthiller, Philippe Paparel, Olivier Chapet
Département of de radiothérapie oncologie, centre hospitalier universitaire Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France; Université de Lyon, 69000 Lyon, France., Service d'urologie, chirurgie de la transplantation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France., Service d'Imagerie Urinaire et Vasculaire, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France., Département de radiothérapie oncologique, institut Curie, 26, rue d'Ulm, 75005 Paris, France., Service de Recherche et d'Epidemiologie Clinique, Pole de Santé Publique, Hospices Civils de Lyon. Electronic address: ., Department of Urology, CHU Lyon Sud, Pierre-Bénite, France., Département of de radiothérapie oncologie, centre hospitalier universitaire Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France; Université de Lyon, 69000 Lyon, France. Electronic address: .